Heading to market
TRI-01 — Precision gut-brain activator
A shelf-stable active that selectively induces a named four-species consortium of butyrate-producing gut bacteria. Gut-health claims at launch; gut-brain as the evidence builds. Self-Affirmed GRAS pathway; first revenue targeted Q1 2027.
TRI-04 — Low-MW prebiotic fibre
A water-soluble prebiotic fibre that supports the gut's butyrate-producing bacteria, with a metabolic-health (GLP-1 axis) claim path under study. Lean Self-Affirmed GRAS pathway; first revenue targeted Q1 2027.
In development
A pipeline of precision bioactives across nutraceutical and cosmeceutical applications — from discovery to development. See the pipeline →
Shared by design
Every active shares the same DNA: species- or network-level precision, milligram-to-low-gram dosing, shelf-stability, clean extraction from upcycled side-streams, and a substantiation pathway. They come from one engine — Teroka (see /platform).
Partner with us → The science →
FAQ
- What ingredients does Trilliome offer? Two market-bound actives — TRI-01 (gut-brain activator) and TRI-04 (low-MW prebiotic fibre) — plus a development pipeline.
- What's the difference between TRI-01 and TRI-04? TRI-01 induces specific named species directly at milligram doses; TRI-04 is a water-soluble prebiotic fibre that nourishes the broader community of butyrate-producing bacteria.
- Are the pipeline products available? Not yet — they range from discovery to development, without committed launch dates.